BMEA Biomea Fusion Inc
Company Analysis
Latest News
🟢 Biomea Fusion is trading 7.66% up with no identified catalyst
Biomea Fusion is trading at $0.63, up +7.66%, with the reason for its October 23 gain unclear. - No company-specific announcement explaining the October 23...
🟢 Biomea Fusion is trading 14.97% up in pre-market
Biomea Fusion is trading at $0.67, up 14.97% in pre-market, with no identified company-specific announcement explaining the October 23 move. - The latest...
🟢 Biomea Fusion is trading 7.74% up in pre-market
Biomea Fusion is trading at $0.63, up 7.74% in pre-market, with no company-specific announcement explaining the October 23 rise identified in available...
🔴 Biomea Fusion is trading 11.5% down today during a broader risk-off session
Biomea Fusion is trading at $0.61, down 11.53%, during a broader risk-off session, though no company-specific cause is confirmed. - Reuters reported...
🔴 Biomea Fusion is trading 5.38% down on October 22 as tech stocks and U.S. indexes fell
Biomea Fusion is trading at $0.65, down 5.38%, amid a broad risk-off session; the market backdrop is the clearest available explanation, not a confirmed...
Biomea Fusion Wins FDA Fast Track for BMF-219 Solid Tumor Treatment
Biomea Fusion Inc. announced that the FDA granted Fast Track designation to its lead investigational drug, BMF-219, for an undisclosed type of solid...
🔴 Biomea Fusion is trading 6.9% down
Biomea Fusion is trading at $0.68, with a -6.93% change; the reason for the decline is uncertain. - No new company-specific announcement was identified for...
🟢 Biomea Fusion is trading 8.62% up in pre-market amid biotech gains; catalyst remains uncertain
Biomea Fusion is trading at $0.80, up +8.62% pre-market, amid a 3.64% pre-market rise in biotech; the move’s catalyst remains uncertain. - No new...
🟢 Biomea Fusion is trading 12.23% up in after-hours trading
Biomea Fusion is trading 12.23% up in after-hours trading at $0.83, with no confirmed catalyst identified. - The stock closed the regular session at $0.74 on...
🔴 Biomea Fusion is trading 10.4% down with no confirmed catalyst
Biomea Fusion is trading at $0.75, down 10.40%, with no specific catalyst confirmed. - No clear company announcement explaining the October 20 decline has...
🔴 Biomea Fusion is trading 7.84% down
Biomea Fusion is trading 7.84% down at $0.77 on October 20, 2026, with no clear company-specific announcement identified to explain the decline. - The latest...
🟢 Biomea Fusion is trading 7.71% up today with no company-specific catalyst identified
Biomea Fusion is trading at $0.90, up 7.71% as of 10:59 a.m. ET on October 20, 2026; no company-specific announcement explaining the gain was found, while...
🟢 Biomea Fusion is trading 14.6% up; catalyst remains unclear
Biomea Fusion is trading 14.6% up at $0.96, with no clear catalyst identified for the October 16, 2026 move. - The latest major company news was Phase 1...
🟢 Biomea Fusion is trading 8.5% up
Biomea Fusion is trading at $0.91, up 8.50%, with no identified company-specific announcement explaining the October 16 move. - The gain follows the sharp...
🟢 Biomea Fusion is trading 5.5% up today, rebounding after public offering and Phase 1 data selloff
Biomea Fusion is trading 5.5% up at $0.88, rebounding from its October 14 close of $0.83 after the prior session’s selloff. * The prior session's sharp...
🔴 Biomea Fusion is trading 30.46% down after BMF-650 Phase 1 results
Biomea Fusion is trading at $0.88, down 30.46%, following the company’s announcement of Phase 1 results for oral GLP-1 candidate BMF-650; available coverage...
Biomea Fusion Announces Positive Phase 1 Results for Oral GLP-1 Drug BMF-650
Biomea Fusion announced topline results from its Phase 1 clinical trial (GLP-131) for BMF-650, an investigational oral GLP-1 receptor agonist for obesity. The...
🔴 Biomea Fusion is trading 30.2% down in pre-market with BMF-650 results a possible catalyst
Biomea Fusion is trading 30.2% lower at $0.88 after preliminary October 13 Phase 1 results for oral obesity candidate BMF-650, a possible catalyst, though...
Biomea Fusion Reports Up to 3.2% Weight Loss in Obesity Trial
Biomea Fusion reported positive topline results from a Phase 1 study of its experimental oral obesity drug, BMF-650. In the first four weeks, participants...
🔴 Biomea Fusion is trading 20.6% down in after-hours trading with Phase I results call scheduled
Biomea Fusion is trading 20.6% down at $1.00 after the October 13 regular-session close; no verified company-specific explanation for the after-hours move was...